• Inspira Pharmaceuticals has moved into Stevenage Bioscience Catalyst’s Lab Hotel to develop its IPX enzyme technology
• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months
• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.
Stevenage Bioscience Catalyst (SBC) has welcomed Inspira Pharmaceuticals to its Lab Hotel, a unique facility offering free lab and office accommodation for six months. The start-ups receive scientific and business support…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF
HIGH CONCENTRATION HUMIRA® BIOSIMILAR
- Patents demonstrate strength of innovative ArestatTM technology and its potential in development of enhanced formulations of high value biologics
- Further strengthens Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and proprietary products
Cambridge, UK, 9 August 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to…
Learn to Discover (L2D) is a cutting edge course, specifically targeted at bioscience and medicine professionals, equipping individuals with powerful skills in Python programming, data science, machine learning and aspects of AI, aimed at furthering your research.
Created and delivered by a team of expert research scientists, a rich curriculum of weekly lectures, live webinars, exercises and assignments is paired with one on one tutor guided support.
Thus L2D caters to students of all levels of previous programming experience and allows individuals to pace their learning as they see fit. A…
Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
“We are delighted that the Cypex team is joining BioIVT, bringing with them not…
Intellectual property offices worldwide are now enforcing the World Intellectual Property Organization (WIPO) Standard ST.26, which prescribes requirements for the presentation of nucleotide and amino acid sequence listings in patent applications. The new standard applies to patent applications filed on or after 1 July 2022 (the “big bang” date).
Standard ST.26 (hereinafter, “ST.26”) is intended to establish a single format for sequence listings that is acceptable worldwide and is compatible with international databases, such as those maintained by the International Nucleotide Sequence…
Leading global drug development consultancy Boyds has bolstered its US team with the appointment of experienced pharmaceutical product development professional Ami Patel PhD.
With more than 15 years’ experience in the pharmaceutical industry, Ami joins Boyds as Senior Director of Product Development based at the company’s Philadelphia office.
Ami has a PhD in Pharmaceutics from Long Island University, Brooklyn. Her career experience spans formulation research and development, business development and project management and technical consulting, with specialist expertise in product…
An independent study on European/UK growth stage Biotech remuneration
PIR International’s 2022 EU/UK Biotech Board & Executive Remuneration Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in the sector.…
BioIVT, LLC (“BioIVT”), a leading global provider of biospecimens, cell and gene therapy related products, and research models and services for drug development purposes, today announced the promotion of Richard Haigh, PhD, to Chief Executive Officer (CEO) effective August 1. Dr. Haigh joined BioIVT in May 2022 as Chief Operating Officer and brings over 27 years’ experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years with Thermo Fisher Scientific/Life Technologies.
“I am delighted and honored to be taking on the…
Cambridge UK: 27 July 2022
RSM UK has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Laragh Jeanroy, Managing Partner RSM East Anglia and Co-Head of Life Sciences at RSM commented
‘As a respected industry body for the life sciences industry and a key driver of business in the Cambridge and wider region, we are really pleased to become a partner of One Nucleus and excited to explore opportunities for…